TAIWAN PRECISION MEDICINE CORPORATION
Update：2026/10/21
Industries
Main Industry
Biotechnology
Main Product/Service
Clinically validated through large-scale studies, the RecurIndex® Genomic Assay analyzes the gene expression profiles of gene groups most closely associated with breast cancer recurrence in Asian populations. By integrating this with clinical data* for comprehensive analysis, it can predict the probability of "local recurrence" and "distant metastasis" of breast cancer within the next 5 years. This enables physicians and patients to understand the biological characteristics of the tumor at an early stage, serving as an important reference for subsequent treatment decisions.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2015
Unified Business No.
42658554
Status
Closed
Number of Employees
0
Total Paid-in
Capital
173,481,520 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
